The increase in price target from $22 to $24 by a reputable analyst firm like HC Wainwright & Co. suggests a positive outlook on NovoCure's stock value in the short term. Although the rating remains Neutral, the adjustment in price target indicates an expectation of some upward movement in NVCR's stock price, likely driven by factors that the analyst has identified as positive. This could lead to increased investor interest and potentially a short-term increase in stock price.